The final months of 2025 could mark a defining chapter in Zymeworks Inc.'s (ZYME) story. With topline data from the HERIZON-GEA-01 trial expected before year-end, the company stands on the cusp of a potential breakthrough in HER2-positive gastroesophageal adenocarcinoma (GEA), a notoriously aggressive cancer with limited first-line treatment options.
At the heart of this moment is zanidatamab, a bispecific antibody engineered to target HER2 with dual precision. If the trial delivers, it won't just validate the molecule's therapeutic promise, it could signal a new era for Zymeworks, one where royalty streams and global access converge to reshape its long-term strategy.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.